General Information and Variability Data of DT
DT ID DTD0004
Gene Name ABCG2
Protein Name Breast cancer resistance protein
Synonyms ABC15; ABCG2; ABCP; ATP-binding cassette sub-family G member 2; BCRP; BCRP1; BMDP; CD338; CDw338; EST157481; GOUT1; MRX; MXR; MXR-1; MXR1; Mitoxantrone resistance-associated protein; Placenta-specific ATP-binding cassette transporter; UAQTL1; Urate exporter
Gene ID
9429
UniProt ID
Q9UNQ0
TCDB ID
3.A.1.204.2
DT Family ATP-Binding Cassette (ABC) Superfamily
Eye Pigment Precursor Transporter (EPP) Family (ABCG)
Tissue Specificity Intestinal enterocyte, hepatocyte (canalicular), kidney proximal tubule, brain endothelia, placenta, stem cells, mammary gland (lactating), expressed at high levels on the apical surface of many tumor cell lines
Function This transporter functioned in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.
Disease(s) Amyotrophic lateral sclerosis [ICD-11: 8B60.0]
Colorectal cancer [ICD-11: 2B91]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Onchocerciasis [ICD-11: 1F6A]
Osteoporosis [ICD-11: FB83.1]
Pemphigus vulgaris [ICD-11: EB40.0]
Pulmonary arterial hypertension [ICD-11: BB01.0]
Chronic bronchitis [ICD-11: CA20.1]
Termination of pregnancy [ICD-11: KD3A]
Genetic Polymorphisms & Epigenetic Regulations of DT
Species-, Tissue- and Disease-specific Protein Abundances of DT
Exogenous Factor Altering DT Activity
Approved Drug(s) Transported by This DT Abacavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [1]
Acyclovir Drug Info Shingles [ICD-11: 1.00E+91] Approved [2]
Adefovir Drug Info Herpes simplex virus infection [ICD-11: 1F00] Approved [3]
Afatinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [4]
Alfuzosin Drug Info Benign prostatic hyperplasia [ICD-11: GA90] Approved [5]
Apatinib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [6]
Apixaban Drug Info Thrombosis [ICD-11: BD71.4, BD72] Approved [7]
Baricitinib Drug Info Psoriasis [ICD-11: EA90] Approved [8]
Bicalutamide Drug Info Prostate cancer [ICD-11: 2C82] Approved [9]
Binimetinib Drug Info Melanoma [ICD-11: 2C30] Approved [10]
Brigatinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [11]
Bupropion Drug Info Smoking cessation [ICD-11: 6C4A.2] Approved [12]
Canagliflozin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [13]
Cephalothin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [14]
Cerivastatin Drug Info Hyperlipidaemia [ICD-11: 5C8Z] Approved [15]
Chlorothiazide Drug Info Edema associated with congestive heart failure [ICD-11: BD10] Approved [16]
Cholic acid Drug Info Synthesis disorders [ICD-11: 5C52.10] Approved [17]
Cimetidine Drug Info Acid reflux disorder [ICD-11: DA22] Approved [18]
Ciprofloxacin Drug Info Seizure [ICD-11: 8A68] Approved [19]
Cisplatin Drug Info Testicular cancer [ICD-11: 2C80] Approved [20]
Cladribine Drug Info Hairy cell leukemia [ICD-11: 2A82.2] Approved [21]
Clofarabine Drug Info Juvenile myelomonocytic leukemia [ICD-11: 2A42] Approved [21]
Cyclosporine Drug Info Xerophthalmia [ICD-11: 5B55.Y] Approved [15]
Dabrafenib Drug Info Melanoma [ICD-11: 2C30] Approved [22]
Dactinomycin Drug Info Cancer [ICD-11: 2A00-2F9Z] Approved [23]
Dasatinib Drug Info Multiple myeloma [ICD-11: 2A83] Approved [24]
Daunorubicin Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [25]
Dehydroepiandrosterone sulfate Drug Info Dyspareunia [ICD-11: GA12] Approved [26]
Delavirdine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [15]
Deoxycholic acid Drug Info Fat below the chin [ICD-11: 5B80] Approved [14]
Diclofenac Drug Info Osteoarthritis of knee [ICD-11: FA01] Approved [27]
Dipyridamole Drug Info High blood pressure [ICD-11: BA00] Approved [28]
Dirithromycin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [14]
Docetaxel Drug Info Lung cancer [ICD-11: 2C25] Approved [29]
Doxorubicin Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [30]
Eltrombopag Drug Info Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved [31]
Empagliflozin Drug Info Type 1 diabetes [ICD-11: 5A10] Approved [32]
Entacapone Drug Info Parkinson's Disease [ICD-11: 8A00.0] Approved [33]
Entecavir Drug Info Chronic hepatitis B infection [ICD-11: 1E51.0] Approved [34]
Epirubicin Drug Info Node-positive breast cancer [ICD-11: 2C60-2C6Z] Approved [15]
Erlotinib Drug Info Non-small cell lung cancer [ICD-11: 2C25] Approved [35]
Erythromycin Drug Info Pelvic inflammatory disease [ICD-11: GA05] Approved [28]
Estradiol Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [36]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [37]
Estrone sulfate Drug Info Menopausal symptoms [ICD-11: MF32] Approved [38]
Etoposide Drug Info Testicular cancer [ICD-11: 2C80] Approved [39]
Ezetimibe Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [40]
Fluorouracil Drug Info Stomach cancer [ICD-11: 2B72] Approved [41]
Fluvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [42]
Folic acid Drug Info Vitamin deficiency [ICD-11: 5B55-5B7Z] Approved [43]
Ganciclovir Drug Info Cytomegalovirus infections [ICD-11: 1D82] Approved [44]
Gefitinib Drug Info Urethral cancer [ICD-11: 2F78] Approved [15]
Glibenclamide Drug Info Diabetes [ICD-11: 5A10-5A14] Approved [45]
Glutathione Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [46]
Grepafloxacin Drug Info Chronic bronchitis [ICD-11: CA20.1] Approved [47]
Hesperetin Drug Info High cholesterol level [ICD-11: 5C80.00] Approved [48]
Hydroxychloroquine Drug Info Malaria [ICD-11: 1F40] Approved [49]
Idarubicin Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [50]
Idelalisib Drug Info Chronic lymphocytic leukemia [ICD-11: 2A82.0] Approved [51]
Imatinib Drug Info Gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [52]
Irinotecan Drug Info Colorectal cancer [ICD-11: 2B91] Approved [53]
Lamivudine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [54]
Lapatinib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [55]
Leflunomide Drug Info Multiple scierosis [ICD-11: 8A40] Approved [56]
Lopinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [15]
Menadione Drug Info Vitamin K deficiency [ICD-11: 5B59] Approved [57]
Mercaptopurine Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [3]
Metformin Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [58]
Methotrexate Drug Info Leukemia [ICD-11: 2A60-2B33] Approved [59]
Mitoxantrone Drug Info Metastatic breast cancer [ICD-11: 2C6Y] Approved [25]
Moxidectin Drug Info Onchocerciasis [ICD-11: 1F6A] Approved [60]
Mycophenolate mofetil Drug Info Pemphigus vulgaris [ICD-11: EB40.0] Approved [61]
Nelfinavir Drug Info Sars coronavirus infections [ICD-11: 1D92] Approved [15]
Nicardipine Drug Info High blood pressure [ICD-11: BA00] Approved [15]
Nilotinib Drug Info Chronic myelogenous leukemia [ICD-11: 2A20.0] Approved [24]
Nitrofurantoin Drug Info Termination of pregnancy [ICD-11: KD3A] Approved [62]
Norfloxacin Drug Info Urinary tract infections [ICD-11: GC08] Approved [63]
Ofloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Approved [15]
Olmesartan medoxomil Drug Info High blood pressure [ICD-11: BA00] Approved [32]
Oxaliplatin Drug Info Colorectal cancer [ICD-11: 2B91] Approved [64]
Paclitaxel Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [29]
Palbociclib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [65]
Pantoprazole Drug Info Gastroesophageal reflux disease [ICD-11: DA22] Approved [66]
Pazopanib hydrochloride Drug Info Renal cell carcinoma [ICD-11: 2C90] Approved [67]
Pemetrexed Drug Info Malignant pleural mesothelioma [ICD-11: 2C26.0] Approved [68]
Pirarubicin Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [41]
Pitavastatin Drug Info Primary hyperlipidemia and mixed dyslipidemia [ICD-11: 5C8Z] Approved [28]
Pitavastatin calcium Drug Info Dyslipidaemias [ICD-11: 5C8Z] Approved [69]
Ponatinib Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [70]
Prasterone Drug Info Hypercalcemia [ICD-11: 5B91.0] Approved [71]
Pravastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [15]
Prazosin Drug Info Severe congestive heart failure [ICD-11: BD10] Approved [72]
Progesterone Drug Info Premature labour [ICD-11: JB00] Approved [36]
Pyrimethamine Drug Info Isosporiasis [ICD-11: 1A33.Z] Approved [73]
Quercetin Drug Info Coronary artery disease [ICD-11: BA6Z] Approved [15]
Rabeprazole Drug Info Gastroesophageal reflux disease [ICD-11: DA22] Approved [74]
Raltitrexed Drug Info Rectal cancer [ICD-11: 2B92] Approved [75]
Regorafenib Drug Info Metastatic colorectal cancer [ICD-11: 2B91] Approved [32]
Reserpine Drug Info High blood pressure [ICD-11: BA00] Approved [15]
Riboflavin Drug Info Acne vulgaris [ICD-11: ED80] Approved [76]
Rifampicin Drug Info Tuberculosis [ICD-11: 1B1Z] Approved [14]
Riluzole Drug Info Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved [77]
Riociguat Drug Info Pulmonary arterial hypertension [ICD-11: BB01.0] Approved [32]
Rivaroxaban Drug Info Prophylaxis of deep vein thrombosis [ICD-11: BD71] Approved [78]
Rosiglitazone Drug Info Type 2 diabetes [ICD-11: 5A11] Approved [79]
Rosuvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [80]
Saquinavir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [81]
Simvastatin Drug Info Hypercholesterolemia [ICD-11: 5C80.0] Approved [71]
Sofosbuvir Drug Info Chronic hepatitis C infection [ICD-11: 1E51.1] Approved [32]
Sorafenib Drug Info Pancreatic cancer [ICD-11: 2C10] Approved [82]
Sulfasalazine Drug Info Rheumatoid arthritis [ICD-11: FA20] Approved [83]
Sunitinib Drug Info Imatinib-resistant gastrointestinal stromal tumor [ICD-11: 2B5B] Approved [82]
Talazoparib Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [84]
Tamoxifen Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Approved [85]
Teniposide Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [15]
Tenofovir Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [32]
Teriflunomide Drug Info Multiple scierosis [ICD-11: 8A40] Approved [49]
Testosterone Drug Info Osteoporosis [ICD-11: FB83.1] Approved [86]
Tetracycline Drug Info Gram-positive & negative bacteria infections [ICD-11: 1A00-1H0Z] Approved [14]
Thioguanine Drug Info Acute myeloid leukemia [ICD-11: 2A60] Approved [3]
Topotecan Drug Info Ovarian cancer [ICD-11: 2C73] Approved [87]
Trimetrexate Drug Info Pneumocystis carinii pneumonia [ICD-11: CA40.20] Approved [73]
Vandetanib Drug Info Thyroid gland tumours [ICD-11: 2D10] Approved [88]
Verteporfin Drug Info Age-related macular degeneration [ICD-11: 9B75.0] Approved [89]
Vinblastine Drug Info Testicular cancer [ICD-11: 2C80] Approved [29]
Vincristine Drug Info Acute lymphoblastic leukemia [ICD-11: 2B33.0] Approved [73]
Zidovudine Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Approved [15]
Clinical Trial Drug(s) Transported by This DT Daidzein Drug Info Low Serum Lipid Levels [ICD-11: 5C81] Phase 4 [90]
Hypericin Drug Info Subclinical anxious adults [ICD-11: 6A73] Phase 4 [91]
Nifurtimox Drug Info Human african trypanosomiasis [ICD-11: 1F51] Phase 4 [92]
AG 337 Drug Info Lung cancer [ICD-11: 2C25] Phase 3 [73]
Belotecan Drug Info Non-small cell lung cancer [ICD-11: 2C25] Phase 3 [93]
Camptothecin Drug Info Non-small cell lung cancer [ICD-11: 2C25] Phase 3 [94]
Exatecan mesylate Drug Info Pancreatic cancer [ICD-11: 2C10] Phase 3 [75]
Glycocholic acid Drug Info Bile acid synthesis defect [ICD-11: 5C52.11] Phase 3 [17]
J-107088 Drug Info Glioblastoma [ICD-11: 2A00.0] Phase 3 [75]
Karenitecin Drug Info Ovarian cancer [ICD-11: 2C73] Phase 3 [75]
Phenethyl isothiocyanate Drug Info Cancer [ICD-11: 2A00-2F9Z] Phase 3 [26]
Tenofovir alafenamide Drug Info Human immunodeficiency virus infection [ICD-11: 1C62.Z] Phase 3 [95]
Butyrate Drug Info Schizophrenia [ICD-11: 6A20] Phase 2/3 [96]
Uric acid Drug Info Acute ischemic stroke [ICD-11: 8B11] Phase 2/3 [97]
9-Aminocamptothecin Drug Info Ovarian cancer [ICD-11: 2C73] Phase 2 [75]
Bisantrene Drug Info Acute myelogenous leukemia [ICD-11: 2B33.1] Phase 2 [75]
BN-80915 Drug Info Non-small cell lung cancer [ICD-11: 2C25] Phase 2 [75]
C-1311 Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Phase 2 [98]
Cholesterol Drug Info Cone-Rod dystrophy [ICD-11: 9B70] Phase 2 [36]
Flavopiridol Drug Info Chronic lymphocytic leukemia [ICD-11: 2A82.0] Phase 2 [99]
Genistein Drug Info Prostate cancer [ICD-11: 2C82] Phase 2 [38]
HPPH Drug Info Lung cancer [ICD-11: 2C25] Phase 2 [100]
Ortataxel Drug Info Glioblastoma [ICD-11: 2A00.0] Phase 2 [15]
Oxfendazole Drug Info Trichuris infection [ICD-11: 1F6G] Phase 2 [101]
Phosphatidylserine Drug Info Familial dysautonomia [ICD-11: 8C21] Phase 2 [102]
Piritrexim Drug Info Urethral cancer [ICD-11: 2F78] Phase 2 [73]
Quinacrine Drug Info Prostate cancer [ICD-11: 2C82] Phase 2 [14]
SJG-136 Drug Info Recurrent fallopian tube cancer [ICD-11: 2C74] Phase 2 [103]
SN-38 Drug Info Colon cancer [ICD-11: 2B90.Z] Phase 2 [104]
UCN-01 Drug Info Non-small cell lung cancer [ICD-11: 2C25] Phase 2 [75]
Gimatecan Drug Info Brain and central nervous system tumors [ICD-11: 2A00] Phase 1/2 [75]
Benzo(a)pyrene Drug Info Environmental exposure [ICD-11: NF08.Z] Phase 1 [26]
Benzoylphenylurea Drug Info Solid tumours [ICD-11: 2D4Z] Phase 1 [105]
CP-724714 Drug Info Breast cancer [ICD-11: 2C60-2C6Z] Phase 1 [106]
Mycophenolic acid glucuronide Drug Info Lung transplantation [ICD-11: QB63.2] Phase 1 [61]
Sphingosine-1-phosphate Drug Info Acne vulgaris [ICD-11: ED80] Phase 1 [107]
Withdrawn, Discontinued or Preclinical Drug(s) Transported by This DT Parabis Drug Info Tapeworm infestation [ICD-11: 1F7Y] Withdrawn [108]
Becatecarin Drug Info Solid tumours [ICD-11: 2D4Z] Discontinued in Phase 3 [109]
Befloxatone Drug Info Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3 [110]
E3040 Drug Info Thrombosis [ICD-11: BD71.4, BD72] Discontinued in Phase 2 [111]
Lurtotecan Drug Info Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2 [26]
NB-506 Drug Info Solid tumours [ICD-11: 2D4Z] Discontinued in Phase 2 [75]
Resveratrol Drug Info Colorectal cancer [ICD-11: 2B91] Discontinued in Phase 2 [43]
Rhodamine 123 Drug Info Prostate cancer [ICD-11: 2C82] Discontinued in Phase 1 [112]
AG1478 Drug Info Nasopharyngeal carcinoma [ICD-11: 2B6B] Preclinical [20]
Azidothymidine monophosphate Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [111]
Barasertib-hQPA Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [113]
BMS 536924 Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [114]
Coumestrol Drug Info Prostate cancer [ICD-11: 2C82] Preclinical [90]
Enrofloxacin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Preclinical [115]
Homocamptothecin Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [116]
JNJ 7706621 Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [117]
N-desethyl sunitinib Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [118]
Pancratistatin Drug Info Cancer [ICD-11: 2A00-2F9Z] Preclinical [119]
Protoporphyrin Drug Info Iron deficiency [ICD-11: 5B5K.0] Preclinical [75]
Puromycin Drug Info Bacterial infections [ICD-11: 1A00-1H0Z] Preclinical [26]
Scutellarin Drug Info Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical [120]
Taurocholic acid Drug Info Type 2 diabetes [ICD-11: 5A11] Terminated [17]
Endogenous Substrate(s) Bisbenzimide; Pheophorbide A
Endogenous Metabolites (EMs) Handled by This DT Hippuric acid EM Info Identified using Abcg2 knockout mice [121]
Indoxyl sulfate EM Info Identified using Abcg2 knockout mice [121]
Drug-DT Affinity Assessed by Cell Line
Drug(s) with Drug-DT Affinity Data Daunorubicin Drug Info Spodoptera frugiperda (Sf9) cells-BCRP Km = 2.5 microM [25]
Doxorubicin Drug Info Spodoptera frugiperda (Sf9) cells-BCRP Km = 5 microM [25]
Estradiol-17beta-glucuronide Drug Info Human embryonic kidney cells (HEK293)-BCRP Km = 44.2 microM [122]
Estrone sulfate Drug Info Mouse lymphoma cells (P388)-BCRP Km = 16.6 microM [37]
Estrone sulfate Drug Info Myelogenous leukemia cells (K562)-BCRP Km = 6.8 microM [123]
Hematoporphyrin Drug Info Spodoptera frugiperda (Sf9) cells-BCRP Km = 17.8 microM [124]
Methotrexate Drug Info Breast carcinoma cell line (MCF7)-BCRP Km = 681 microM [59]
Methotrexate Drug Info Human embryonic kidney cells (HEK293)-BCRP Km = 1340 microM [122]
Methotrexate Drug Info Human embryonic kidney cells (HEK293)-BCRP Km = 1410 microM [125]
Mitoxantrone Drug Info Spodoptera frugiperda (Sf9) cells-BCRP Km = 7 microM [25]
Pitavastatin calcium Drug Info Human embryonic kidney cells (HEK293)-BCRP Km = 5.73 microM [69]
Rosuvastatin Drug Info Human embryonic kidney cells (HEK293)-BCRP Km = 2.02 microM [80]
Rosuvastatin Drug Info Madin-Darby canine kidney cells (MDCKII)-BCRP Km = 10.1 microM [126]
SN-38 Drug Info Human lung carcinoma cells (PC-6/SN2-5H)-BCRP Km = 4 microM [104]
Sulfasalazine Drug Info Spodoptera frugiperda (Sf9) cells-BCRP Km = 0.7 microM [127]
Topotecan Drug Info Madin-Darby canine kidney cells (MDCKII)-BCRP Km = 213 microM [93]
References
1 QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46.
2 Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011 Sep;89(9):675-80.
3 ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
4 Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
5 In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71.
6 Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91.
7 Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35.
8 Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
9 Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
10 The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
11 NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
12 Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6.
13 In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
14 Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
15 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
16 ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53.
17 Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
18 Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
19 Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
20 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
21 Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
22 Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
23 Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.
24 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
25 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
26 A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
27 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
28 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
29 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
30 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
31 Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51.
32 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
33 Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291.
34 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
35 Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
36 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
37 ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9.
38 Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
39 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
40 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
41 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
42 Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. 2015 May;32(5):1634-47.
43 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
44 Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501.
45 Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8.
46 Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem. 2010 May 28;285(22):16582-7.
47 Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos. 2007 Oct;35(10):1873-9.
48 Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004 Apr 23;317(1):269-75.
49 MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
50 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
51 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB09054)
52 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
53 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
54 The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007 Nov;64(5):645-54.
55 The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
56 Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7.
57 The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3279-86.
58 Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol. 2010 Apr;202(4):383.e1-7.
59 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
60 Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012 Apr 14;2:134-53.
61 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
62 The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64.
63 Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
64 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
65 Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
66 Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.
67 Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
68 pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011 Sep;39(9):1478-85.
69 Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
70 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
71 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
72 P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 2011 Jan 25;1370:238-45.
73 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
74 Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
75 Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
76 Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol. 2007 Feb;27(4):1247-53.
77 Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6.
78 Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
79 ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
80 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
81 Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507.
82 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
83 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
84 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
85 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
86 Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9.
87 Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
88 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
89 The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
90 Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol. 2007 Oct;72(4):967-75.
91 Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009 Dec;8(12):1716-23.
92 The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 2012 Feb 3;1436:111-21.
93 Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
94 The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
95 Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
96 The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. Am J Physiol Cell Physiol. 2011 Nov;301(5):C984-94.
97 Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One. 2012;7(2):e30456.
98 C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol. 2007 Jun 30;74(1):41-53.
99 The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44.
100 Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm. 2010 Oct 4;7(5):1789-804.
101 Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos. 2005 May;33(5):614-8.
102 ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010 Apr 24;86(17-18):631-7.
103 Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J. 2010 Dec;12(4):617-27.
104 Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001 Nov 9;288(4):827-32.
105 American Association for Cancer Research.
106 Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009 Feb;4(2):188-95.
107 Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010 Apr 2;285(14):10477-86.
108 Human and rat ABC transporter efflux of bisphenol a and bisphenol a glucuronide: interspecies comparison and implications for pharmacokinetic assessment. Toxicol Sci. 2012 Aug;128(2):317-25.
109 Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83.
110 Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med. 2011 Mar;52(3):415-23.
111 Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 May 11;7(1):E118-33.
112 Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med. 2017 Mar 17;49(3):e303.
113 P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer. 2011 Jun 16;11:254.
114 Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther. 2011 Jan;10(1):117-25.
115 Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther. 2006 Aug;29(4):279-87.
116 ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007 Mar;26(1):39-57.
117 Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
118 P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012 Apr;341(1):164-73.
119 Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol. 2009 Nov;76(5):946-56.
120 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
121 Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression. Sci Rep. 2018 Jul 24;8(1):11147.
122 Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
123 Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8.
124 Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol. 2006 Jul;70(1):287-96.
125 Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
126 Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res. 2008 Aug;25(8):1807-14.
127 Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. Biol Pharm Bull. 2009 Mar;32(3):497-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.